The Endocrinology Network® Women’s Health clinical resource center is a hub of news and information related to health of women at all ages and stages of life. This page offers perspective and insight on the latest information from multiple fields of women’s health, including gestational diabetes, hormone therapy, menopause management, and reproductive health.
August 06, 2022
On August 5, Pfizer announced the FDA's approval of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg (MYFEMBREE) for the management of moderate to severe pain associated with endometriosis in premenopausal women for up to 24 months.
August 04, 2022
A national coalition of more than 20 health professional organizations and patient representatives, the WPSI recommendation for preventing obesity in midlife women advocates for counseling to maintain weight or limit weight gain among women with normal or overweight BMI aged 40-60 years.
July 30, 2022
Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.
July 21, 2022
Women with endometriosis had a 34% greater risk of stroke than women without the chronic inflammatory gynecological condition, according to an analysis of the Nurses Health Study II.
July 20, 2022
An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
July 08, 2022
Released on July 7, the 2022 hormone therapy position statement from the North American Menopause Society is 28 pages in length and has received endorsement from 20 international organizations, including the AACE.
June 18, 2022
According to a new study, cumulative exposure to PFAS during midlife can increase the risk of incident hypertension among women as they age, with those in the highest tertile of cumulative exposure at a 71% greater risk of developing hypertension.
June 15, 2022
New data from the SKYLIGHT 2 trial demonstrate the reductions in frequency and severity of vasomotor menopausal symptoms in midlife women associated with the use of fezolinetant as well as potential improvements in sleep associated with use of the neurokinin-3 receptor antagonist from Astellas Pharma.
May 24, 2022
Data presented at the European Congress of Endocrinology detail genetic and observational associations between obesity, and markers of body composition on the likelihood of developing PCOS later in life.
April 23, 2022
Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include a multipart video series, new diabetes, information on osteoporosis, and more!